01—Abstract
Summary
Summary of the 8-K filed March 9, 2026. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. (NYSE: WST) announced on March 9, 2026 that Eric M.
Green, its President, Chief Executive Officer and Chair of the Board, informed the Board on March 6, 2026 of his intent to retire from those positions once a successor has been hired. The Board is engaging a leading executive recruiting firm and expects the transition to occur in the second half of 2026. In parallel with the announcement, the Company reaffirmed the 2026 financial guidance it provided in its February 12, 2026 earnings release.
Green, who has served as President and CEO since April 2015 and became Chair in May 2022, said he has confidence in the current leadership team. Robert F. Friel, Lead Independent Director, cited exceptional revenue and enterprise value growth during Green's tenure, including more than doubling the Company's sales and total shareholder return of approximately 350%a.
The filing is primarily a leadership transition notice with a reaffirmation of guidance. It does not name a successor or disclose new financial results. For investors, the key items are the CEO succession timeline and the continued guidance, with the Company's fiscal year 2025 net sales of $3.07 billionb provided for context.
02—Key points
Key Highlights
- CEO and Chair Eric M. Green plans to retire once a successor is hired; he notified the Board on March 6, 2026.
- The Board has engaged a leading executive recruiting firm and expects the transition in the second half of 2026.
- West reaffirmed the 2026 financial guidance from its February 12, 2026 earnings release.
- Green has served as President and CEO since April 2015 and as Chair of the Board since May 2022.
- Lead Independent Director Robert F. Friel cited more than doubled sales and total shareholder return of approximately 350% during Green's tenure.
- Green said he may serve in the future on corporate boards or in advisory roles.
- West reported fiscal year 2025 net sales of $3.07 billion.
03—Questions
Frequently Asked Questions
Who is leaving West Pharmaceutical Services and when?
Eric M. Green, President, Chief Executive Officer and Chair of the Board, plans to retire from those positions once his successor is hired. The Board expects the transition to occur in the second half of 2026.
Has a successor been named?
No. The filing states that the Board is engaging a leading executive recruiting firm to assist with the search for a successor.
Did West change its financial guidance?
No. In parallel with the announcement, the Company reaffirmed the guidance set forth in its February 12, 2026 press release.
What did the Company say about Green's tenure?
Lead Independent Director Robert F. Friel said the tenure was marked by exceptional revenue and enterprise value growth, more than doubled sales, and total shareholder return of approximately 350%. He also cited innovations, the COVID-19 vaccine support response, and expanded global impact.
04—Continue